Drugs News and Research

RSS

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Antibodies neutralize mosquito-transmitted chikungunya virus, researchers reveal

Researchers have learned the precise structure of the mosquito-transmitted chikungunya virus pathogen while it is bound to antibodies, showing how the infection is likely neutralized.

3 Apr 2013

Researchers find association between melatonin, type 2 diabetes

With previous evidence suggesting that melatonin may have a role in glucose metabolism, researchers have found an independent association between decreased secretion of melatonin and an increased risk for the development of type 2 diabetes, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Researchers to test cyclodextrin for treating Niemann-Pick Type C disease

Washington University School of Medicine in St. Louis is playing a leading role in one of the National Institutes of Health's (NIH) first clinical trials to improve treatments for rare and neglected diseases.

3 Apr 2013

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

A team of UC Davis scientists has found that a product resulting from a metabolized omega-3 fatty acid helps combat cancer by cutting off the supply of oxygen and nutrients that fuel tumor growth and spread of the disease.

3 Apr 2013

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

DNA, siRNA and miRNA can reprogram cancer cells - that is, if these nucleic acids could cross through the cell membrane. A University of Colorado Cancer Center study published today in the journal Therapeutic Delivery shows that cholesterol "rafts" can shepherd genetic payloads into cancer cells.

3 Apr 2013

Texas Tech Professor receives NIH grant to research on leishmaniasis

A Texas Tech University biology professor received a five-year, $1.6 million grant from the National Institutes of Health to study the biochemistry of a microscopic parasite responsible for the tropical disease leishmaniasis in the hope of finding a cure.

2 Apr 2013

Study: Pradaxa drug may increase risk and severity of viral infections

A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults.

2 Apr 2013

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.

2 Apr 2013

Discovery of new signalling pathway creates hope for hormone therapy resistance

A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.

2 Apr 2013

First Edition: April 2, 2013

Kaiser Health News consumer columnist Michelle Andrews answers readers' questions about the new marketplaces where consumers can buy 2014 health policies as part of the federal health law. (Andrews, 4/2).

2 Apr 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.

2 Apr 2013

Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

An estimated 20 million Americans have chronic heartburn. About 2 million of these people have Barrett's esophagus, a precancerous condition that affects the tube that carries food from the mouth to the stomach.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

India's Supreme Court rules against Novartis AG in 'landmark' patent case

"India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines," the Associated Press reports.

2 Apr 2013

MIT scientists model structure of alpha synuclein protein associated with Parkinson's

Clumps of proteins that accumulate in brain cells are a hallmark of neurological diseases such as dementia, Parkinson's disease and Alzheimer's disease. Over the past several years, there has been much controversy over the structure of one of those proteins, known as alpha synuclein.

2 Apr 2013

Drugs News and Research

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Antibodies neutralize mosquito-transmitted chikungunya virus, researchers reveal

Researchers find association between melatonin, type 2 diabetes

Researchers to test cyclodextrin for treating Niemann-Pick Type C disease

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

Study shows cholesterol rafts can shepherd genetic payloads into cancer cells

Texas Tech Professor receives NIH grant to research on leishmaniasis

Study: Pradaxa drug may increase risk and severity of viral infections

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

Discovery of new signalling pathway creates hope for hormone therapy resistance

First Edition: April 2, 2013

N30 Pharmaceuticals presents preclinical data of GSNORi at European Cystic Fibrosis Society meeting

Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

India's Supreme Court rules against Novartis AG in 'landmark' patent case

MIT scientists model structure of alpha synuclein protein associated with Parkinson's

Common symptoms in infants are frequently over-treated, researchers say

Sildenafil may also serve as weight loss aid, shows new research

LabCorp launches expanded IBD testing profile

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News